Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing–remitting multiple sclerosis subjects
Open Access
- 1 November 2011
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 11 (11) , 1796-1801
Abstract
No abstract availableKeywords
Funding Information
- ApoPharma, Inc. (SML)
- National Multiple Sclerosis Society (New York, USA) (SML)
- National Institute of Aging (AG23946)
This publication has 24 references indexed in Scilit:
- Effect of IFN-ß therapy on the frequency and function of CD4+CD25+ regulatory T cells and Foxp3 gene expression in relapsing–remitting multiple sclerosis (RRMS): A preliminary studyJournal of Neuroimmunology, 2010
- The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?Annals of Neurology, 2009
- Relapse Management in Multiple SclerosisThe Neurologist, 2009
- Corticosteroids and plasma exchange in multiple sclerosisJournal of Neurology, 2008
- Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitisMultiple Sclerosis Journal, 2007
- EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapsesEuropean Journal of Neurology, 2005
- Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent diseaseJournal of Neuroimmunology, 2001
- Changes in Activated T Cells in the Blood Correlate With Disease Activity in Multiple SclerosisArchives of Neurology, 2000
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects.Journal of Neurology, Neurosurgery & Psychiatry, 1988